COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
|
|
- Stephany Shields
- 5 years ago
- Views:
Transcription
1 COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
2 GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial Assessment 3. Evidence Supporting Prevention & Maintenance Therapy 4. Management of Stable COPD 5. Management of Exacerbations 6. COPD and Comorbidities
3 COPD Definition Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
4 COPD Etiology, Pathobiology & Pathology
5 GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial Assessment 3. Evidence Supporting Prevention & Maintenance Therapy 4. Management of Stable COPD 5. Management of Exacerbations 6. COPD and Comorbidities
6 Diagnosis and Initial Assessment 2017 Global Initiative for Chronic Obstructive Lung Disease
7 Diagnosis and Initial Assessment COPD should be considered in any patient who has dyspnoea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation. The goals of COPD assessment are to determine the level of airflow limitation, the impact of disease on the patient s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.
8 Diagnosis and Initial Assessment Symptoms of COPD Chronic and progressive dyspnoea Cough Sputum production Wheezing and chest tightness Others including fatigue, weight loss, anorexia, syncope, rib fractures, ankle swelling, depression, anxiety Global Initiative for Chronic Obstructive Lung Disease
9 Spirometry 2017 Global Initiative for Chronic Obstructive Lung Disease
10 Classification of severity of airflow limitation 2017 Global Initiative for Chronic Obstructive Lung Disease
11 Choice of breathlessness assessments COPD Assessment Test (CAT TM ) Chronic Respiratory Questionnaire (CCQ ) St George s Respiratory Questionnaire (SGRQ) Chronic Respiratory Questionnaire (CRQ) Modified Medical Research Council (mmrc) questionnaire
12
13 Assessment of Exacerbation Risk COPD exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy. Classified as: Mild (treated with SABDs only) Moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or Severe (patient requires hospitalization or visits the emergency room). Severe exacerbations may also be associated with acute respiratory failure. Blood eosinophil count may also predict exacerbation rates (in patients treated with LABA without ICS).
14 ABCD Assessment Tool
15 GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial Assessment 3. Evidence Supporting Prevention & Maintenance Therapy 4. Management of Stable COPD 5. Management of Exacerbations 6. COPD and Comorbidities
16 KEY POINTS (1 of 3): Evidence Supporting Prevention & Maintenance Therapy Smoking cessation is key. Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates. Pharmacologic therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance. Each pharmacologic treatment regimen should be individualized and guided by the severity of symptoms, risk of exacerbations, sideeffects, comorbidities, drug availability and cost, and the patient s response, preference and ability to use various drug delivery devices. Inhaler technique needs to be assessed regularly.
17 KEY POINTS (2 of 3): Evidence Supporting Prevention & Maintenance Therapy Influenza vaccination decreases the incidence of LRTI s. Pneumococcal vaccination decreases LRTI s. Pulmonary rehabilitation improves symptoms, quality of life, and physical and emotional participation in everyday activities. In patients with severe resting chronic hypoxemia, long-term oxygen therapy improves survival. In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term oxygen treatment should not be prescribed routinely.
18 KEY POINTS (3 of 3): Evidence Supporting Prevention & Maintenance Therapy In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long-term non-invasive ventilation may decrease mortality and prevent re-hospitalization. In select patients with advanced emphysema refractory to optimized medical care, surgical or bronchoscopic interventional treatments may be beneficial. Palliative approaches are effective in controlling symptoms in advanced COPD.
19 Pharmacologic treatment Treatment of Stable COPD
20 Treatment of Stable COPD
21 Pharmacologic treatment: Group A All Group A patients should be offered bronchodilator treatment based on its effect on breathlessness. This can be either a short- or a long-acting bronchodilator. This should be continued if symptomatic benefit is documented Global Initiative for Chronic Obstructive Lung Disease
22 Pharmacologic treatment: Group B Initial therapy should consist of a long acting bronchodilator. LABA s are superior to SABA s taken prn and are therefore recommended. There is no evidence to recommend one class of LABA over another for initial relief of symptoms in this group of patients. In the individual patient, the choice should depend on the patient s perception of symptom relief. For patients with persistent breathlessness on monotherapy the use of two bronchodilators is recommended.
23 Pharmacologic treatment: Group B For patients with severe breathlessness initial therapy with two bronchodilators may be considered. If the addition of a second bronchodilator does not improve symptoms, we suggest the treatment could be stepped down again to a single bronchodilator. Group B patients are likely to have comorbidities that may add to their symptomatology and impact their prognosis, and these possibilities should be investigated.
24 Pharmacologic treatment: Group C Initial therapy should consist of a single long acting bronchodilator. In two head-to head comparisons the tested LAMA was superior to the LABA regarding exacerbation prevention, therefore we recommend starting therapy with a LAMA in this group. Patients with persistent exacerbations may benefit from adding a second long acting bronchodilator (LABA/LAMA) or using a combination of a long acting beta 2 -agonist and an inhaled corticosteroid (LABA/ICS). As ICS increases the risk for developing pneumonia in some patients, our primary choice is LABA/LAMA.
25 Pharmacologic treatment: Group D We recommend starting therapy with a LABA/LAMA combination because: In studies with patient reported outcomes as the primary endpoint LABA/LAMA s showed superior results compared to the single substances. If a single bronchodilator is chosen as initial treatment, a LAMA is preferred for exacerbation prevention based on comparison to LABAs (for details see GOLD 2017 Chapter 3). A LABA/LAMA combination was superior to a LABA/ICS combination in preventing exacerbations and other patient reported outcomes in Group D patients (for details see GOLD 2017 Chapter 3). Group D patients are at higher risk of developing pneumonia when receiving treatment with ICS.
26 Pharmacologic treatment: Group D In some patients initial therapy with LABA/ICS may be the first choice. These patients may have a history and/or findings suggestive of asthma-copd overlap. High blood eosinophil counts may also be considered as a parameter to support the use of ICS. In patients who develop further exacerbations on LABA/LAMA therapy we suggest two alternative pathways: Escalation to LABA/LAMA/ICS. Studies are underway comparing the effects of LABA/LAMA vs. LABA/LAMA/ICS for exacerbation prevention. Switch to LABA/ICS. However, there is no evidence that switching from LABA/LAMA to LABA/ICS results in better exacerbation prevention. If LABA/ICS therapy does not positively impact exacerbations/symptoms, a LAMA can be added.
27 Pharmacologic treatment: Group D If patients treated with LABA/LAMA/ICS still have exacerbations the following options may be considered: Add roflumilast. This may be considered in patients with an FEV1 < 50% predicted and chronic bronchitis, particularly if they have experienced at least one hospitalization for an exacerbation in the previous year. Add a macrolide. The best available evidence exists for the use of azithromycin. Consideration to the development of resistant organisms should be factored into decision making. Stopping ICS. A reported lack of efficacy, an elevated risk of adverse effects (including pneumonia) and evidence showing no significant harm from withdrawal supports this recommendation.
28 Triple Inhaler Therapy Trimbow MDI 87/5/9 TRIBUTE Study Trelegy Ellipta 92/55/22 IMPACT Study
29 Non-Pharmacologic Treatment Education and self-management Physical activity Pulmonary rehabilitation programs Exercise training Self-management education End of life and palliative care Nutritional support Vaccination Oxygen therapy
30 Rehabilitation, Education & Self- Management 2017 Global Initiative for Chronic Obstructive Lung Disease
31
32 Barnet inhaler choices
33 Stable COPD Treatment Guideline Stable COPD Treatment Guidelines Diagnosing COPD Think of diagnosis of COPD for patients who are: over 35 years old cigarette, cannabis or shisha smokers or ex-smokers (>10 pack years) have any of these symptoms: - exertional breathlessness - chronic cough - regular sputum production - freque t i ter bro chitis - wheeze and have no clinical features of asthma (see table below) Exclude other potential diagnoses Physical examination (possible cardiac causes, TB, obstructive sleep apnoea, localised wheeze?lung cancer, clubbing) Chest X-Ray TB / lung cancer Serial peak flow diary 20% or more variation suggests asthma (see below) Bloods i.e. FBC, ESR, TFT (i.e. anaemia, polycythaemia, Hypothyroidism, TB) Consider bronchiectasis if producing large amounts of sputum daily, frequent infections or basal crackles (may also indicate pulmonary fibrosis). (Refer to local bronchiectasis treatment guidelines) Perform spirometry post bronchodilator (see below): Spirometry should be carried out by a healthcare professional competent in its performance. Airflow obstruction is defined as: FEV1/FVC ratio is <0.7 and FEV1 <80% predicted OR FEV1/FVC ratio is <0.7 and FEV1 80% predictedand symptoms present Perform oximetry Diagnose asthma when: serial peak flow measurements show 20% diurnal or day-today variability or spirometry returns back to normal after steroid trial or bronchodilator there is a > 400ml response to bronchodilators (see below) there is a > 400ml response to a steroid trial (see below) READ CODE as ASTHMA H33 Reversibility testing is used to exclude asthma, not diagnose COPD Diagnose COPD when: Diagnose asthma & COPD (ACOS*) when: Consider an alternative Symptomatic Patient has proven airways - At new assessment, the patient responds to diagnosis in: patients under obstruction and bronchodilator / steroid reversibility trial but younger people with age 50: serial peak flow evidence of obstruction remains on spirometry symptoms of COPD COPD rare after treatment optimisation. measurements show no where the FEV1/FVC measure alphasignificant diurnal or day-today variability and - In patients who have been diagnosed with ratiois anti-trypsin COPD, spirometry then found to improve or older people without ask about show variability over time there is a < 400ml response to typical symptoms of cigarette, bronchodilators (see below) or - In patients who have been diagnosed with COPD where the cannabis and asthma, spirometry then found to show fixed there is a < 400ml response to FEV1/FVC ratio is < 0.7 shisha and airway obstruction over time a steroid trial (see below) passive READ CODE as ASTHMA H33 AND smoking READ CODE as COPD H3 COPD H3 (ACOS*) Treat as asthma & COPD *ACOS = Asthma COPD Overlap Syndrome Determine and EMIS Read code disease severity (see table below) Start appropriate treatment (see flowchart overleaf) Reassess diagnosis in view of response to treatment Bronchodilator reversibility Spirometry should be measured before and after an adequate dose of inhaled bronchodilator. Use nebulised bronchodilator 2.5mg 5mg salbutamol. Alternatively, use inhaled bronchodilator (using high doses via a disposable spacer) 4 puffs x 100 micrograms salbutamol. Measure lung function 15 minutes after 2-agonist. Steroid trial to exclude asthma Spirometry must be measured before and within 24 hours of completing an adequate course of steroid. Use oral prednisolone 30mg (non-enteric coated) every morning for 2 weeks. Spirometry Obstructive spirometry is required to make a diagnosis of COPD. NB FEV1/FVC ratio is a net result and obstruction may be masked by obesity. Spirometry is a near patient test and therefore should be performed in the community. Support is available from the Integrated Respiratory Team regarding spirometry services, provision and training. (Refer to local service) Pulse oximetry Measure in any patient with acute or worsening breathlessness to identify new or worsening respiratory failure, the need for admission and to assess the need for referral for Long Term O2 therapy (SaO2 < 92% on air) in stable patients with severe disease (FEV1 < 50%) or new ankle swelling. During acute exacerbations, aim for saturation of 88-92% pending arterial blood gases or range documented on Patient Specific Protocol (PSP). EMIS Read MRC Breathlessness Scale Code 0 No breathlessness 1 Not troubled by breathlessness except on strenuous exertion 173H 2 Short of breath when hurrying or walking up a slight hill 173I 3 Walks slower than contemporaries on level ground because of breathlessness, or 173J has to stop for breath when walking at own pace 4 Stops for breath after walking about 100m or after a few minutes on level ground 173K 5 Too breathless to leave house, or breathless when dressing or undressing 173L Ensure high value treatments are offered to all patients e.g. use the COPD Value Pyramid** as visual prompt **Thorax 2014;69: doi: /thoraxjnl Grading of airflow obstruction Postbronchodilator FEV1 % EMIS Read Post-bronchodilator predicted Code FEV1/FVC ratio <0.7 80% Stage 1 - Mild*** H36 < % Stage 2 - Moderate H37 < % Stage 3 - Severe H38 <0.7 29% Stage 4 Very Severe H39 ***Symptoms should be present to diagnose COPD in people with mild airflow obstruction Produced by the Camden, Haringey and Islington Responsible Respiratory Prescribing Group. Not to be used for commercial or marketing purposes. Strictly for use within the NHS. Page 1 of 4 References: NICE CG101 June 2010 & QS10 February 2016 update: GOLD Guidelines 2017: Camden, Haringey and Islington Stable COPD Treatment Guidelines v5 Updated June 2017; REVIEW DATE: June 2019
34 NCL inhaler choices
35 NCL inhaler choices
36 NCL inhaler choices
37 NCL inhaler choices
38 COPD Mx
39
40 Interventional Therapy in Stable COPD Lung volume reduction surgery (LVRS). LVRS is a surgical procedure in which parts of the lungs are resected to reduce hyperinflation,261 making respiratory muscles more effective pressure generators by improving their mechanical efficiency.
41 Oxygen Therapy & Ventilatory Support in Stable COPD During exacerbations of COPD. NIV is the standard of care for decreasing morbidity and mortality in patients hospitalized with an exacerbation of COPD and acute respiratory failure
42 Palliative, End of Life & Hospice Care In many patients, the disease trajectory in COPD is marked by a gradual decline in health status and increasing symptoms, punctuated by acute exacerbations that are associated with an increased risk of dying. Although mortality rates following hospitalization for an acute exacerbation of COPD are declining, reported rates still vary from 23% to 80%.
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More information62 year old man with a cough! Dr. Aflah Sadikeen Consultant Respiratory Physician Colombo
62 year old man with a cough! Dr. Aflah Sadikeen Consultant Respiratory Physician Colombo History Mr.KS, a 62 year-old, has been feeling unwell - Worsening cough for the last 5 days - Feels out of breath
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease
CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationUPDATE ON GOLD GUIDELINES IN COPD
UPDATE ON GOLD GUIDELINES IN COPD GERARD J. CRINER, MD, FACP, FACCP PROFESSOR, THORACIC MEDICINE & SURGERY TEMPLE UNIVERSITY SCHOOL OF MEDICINE PHILADELPHIA, PA Gerard J. Criner, MD, is Professor and Founding
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to
More informationReferring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL
Referring for specialist respiratory input Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL Respiratory Specialist- who? GPSI Community Team Secondary Care Respiratory physician and
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationChronic Obstructive Pulmonary Disease (COPD) Measures Document
Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationChronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
More informationCommissioning for Better Outcomes in COPD
Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX COPD OUTLINE Definition and Overview Pathophysiology Diagnosis and Assessment Therapeutic
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationWINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT
WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT Thursday, October 25, 2018 Sarah Sungurlu DO Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures I have no actual
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. Bring it with you every time you see a nurse or doctor about your COPD The aim of this plan is to help you have better control of your
More informationNational COPD Audit Programme
National COPD Audit Programme Planning for every breath National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Primary care audit () 2015 17 Data analysis and methodology Section 4: Providing
More informationGuideline Chronic obstructive pulmonary disease in over 16s: diagnosis and management
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Chronic obstructive pulmonary disease in over s: diagnosis and management Draft for consultation, July 0 This guideline covers diagnosing and
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationSelf-management plan for COPD
Sheffield Clinical Commissioning Group Sheffield Teaching Hospitals NHS Foundation Trust Self-management plan for COPD This is your personal management plan The aim of the plan is to help you have better
More informationBTS Guideline for Home Oxygen use in adults Appendix 9 (online only) Key Questions - PICO 10 December 2012
BTS Guideline for Home Oxygen use in adults Appendix 9 (online only) Key Questions - PICO 10 December 2012 Evidence base for Home Oxygen therapy in COPD, non-copd respiratory disease and nonrespiratory
More informationGuideline Chronic obstructive pulmonary disease in over 16s: diagnosis and management
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Chronic obstructive pulmonary disease in over s: diagnosis and management Draft for consultation, February 0 This guideline covers diagnosing
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) Issued: June 2010 NICE clinical guideline 101 guidance.nice.org.uk/cg101
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationCOPD: Applying New Guidelines to Optimizing Evaluation and Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA
CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA GOLD GINA Chronic Obstructive Pulmonary Disease (COPD) COPD is currently the fourth leading cause of death in the world.1 COPD is projected to
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationChronic obstructive pulmonary disease
National Institute for Clinical Excellence Issue date: February 2004 Quick reference guide Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationNICE guideline Published: 5 December 2018 nice.org.uk/guidance/ng115
Chronic obstructive pulmonary disease in over 16s: diagnosis and management NICE guideline Published: 5 December 2018 nice.org.uk/guidance/ng115 NICE 2018. All rights reserved. Subject to Notice of rights
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationSalford COPD Treatment Pathway
Salford COPD Treatment Pathway Development led by Helen Pyne with Salford Asthma and Respiratory Team (SART) Department Respiratory Medicine Salford Royal NHS Foundation Trust Hope Hospital, Stott Lane,
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationChronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) Definition of COPD Airflow obstruction that is: o Not fully reversible o Progressive o Does not change markedly over several months Combination of airway and
More informationCOPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic
COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic Learning Objectives Know the adverse effects of COPD exacerbations Know mainstays
More informationKaren Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management Priority Health
Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) November 29, 2017 Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management Priority Health Top 5 Causes of Death
More informationOver the last several years various national and
Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More information